Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Protein Hydrolyzation and Glycemic Control

This study has been completed.
Information provided by:
Maastricht University Medical Center Identifier:
First received: December 16, 2009
Last updated: NA
Last verified: December 2009
History: No changes posted
The insulinotropic effects of protein hydrolysate/amino acid ingestion have been shown to regulate blood glucose homeostasis in both type 2 diabetes patients and normoglycemic controls. The objective of the study is to investigate the optimal dose of such an insulinotropic mixture.

Condition Intervention
Dietary Supplement: Protein hydrolyzation

Study Type: Interventional
Study Design: Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: The Additional Effects of Protein Hydrolysate Supplementation on Glucose Homeostasis in Type 2 Diabetes

Further study details as provided by Maastricht University Medical Center:

Primary Outcome Measures:
  • Glucose and insulin homeostasis.

Secondary Outcome Measures:
  • Plasma amino acid profiles

Study Start Date: December 2007
Study Completion Date: April 2009
Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo Dietary Supplement: Protein hydrolyzation
Experimental: Intact protein Dietary Supplement: Protein hydrolyzation
Experimental: Protein hydrolysate Dietary Supplement: Protein hydrolyzation


Ages Eligible for Study:   40 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male
  • Age between 40 and 70 years
  • Oral blood glucose lowering medication
  • BMI < 35 kg/m2

Exclusion Criteria:

  • Exogenous insulin use
  • Cardiac disease (any cardiac event in the last 5 years)
  • Diabetic complications (microvascular complications, microalbuminuria: albumin:creatinine ratio >2,5)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01034618

Maastricht University Medical Center+
Maastricht, Limburg, Netherlands, 6229ER
Sponsors and Collaborators
Maastricht University Medical Center
  More Information

Responsible Party: Ralph J.F. Manders, PhD, Maastricht University Medical Center Identifier: NCT01034618     History of Changes
Other Study ID Numbers: 06-3-081
Study First Received: December 16, 2009
Last Updated: December 16, 2009

Keywords provided by Maastricht University Medical Center:
protein hydrolysate processed this record on May 25, 2017